2024. In a prospective, multicenter study, the 31-GEP identified patients at increased risk of tumor recurrence and added significant prognostic value to AJCC staging. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s504. DOI:https://doi.org/10.25251/skin.8.supp.504.